For the quarter ending 2025-09-30, AVTX made $20,390K in revenue. -$30,550K in net income. Net profit margin of -149.83%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenues, net-Product | 0 | - | - | - |
| Total revenues, net | 0 | - | 249 | - |
| Cost of product sales | - | 0 | -714 | 343 |
| Research and development | 13,621 | 14,074 | 9,538 | 4,601 |
| General and administrative | 5,577 | 5,242 | 4,286 | 4,528 |
| Acquired in-process research and development | 0 | 0 | - | 103 |
| Total operating expenses | 19,198 | 19,316 | 13,110 | 9,575 |
| Loss from operations | -19,198 | -19,316 | -12,861 | -9,575 |
| Change in fair value of derivative liability | 12,530 | 2,530 | - | - |
| Interest income, net | 1,117 | 1,102 | 964 | 1,039 |
| Excess of initial warrant fair value over private placement proceeds | 0 | 0 | - | - |
| Change in fair value of warrant liability | 0 | 0 | -36,025 | -112,046 |
| Change in fair value of derivative liability | - | - | -1,100 | -5,040 |
| Private placement transaction costs | 0 | 0 | - | - |
| Other expense, net | -3 | -5 | -5 | - |
| Total other (expense) income, net | -11,416 | -1,433 | 35,884 | 108,045 |
| (loss) income before taxes | -30,614 | -20,749 | 23,023 | 98,470 |
| Income tax expense (benefit) | 11 | 16 | -14 | 7 |
| Net (loss) income | -30,625 | -20,765 | 23,037 | 98,463 |
| Unrealized income on investments, net | 75 | -34 | - | - |
| Comprehensive (loss) income | -30,550 | -20,799 | - | - |
| Net (loss) income per share of common stock - basic (in dollars per share) | -2.19 | -1.92 | 0.98 | 4.21 |
| Net loss per share of common stock - diluted (in dollars per share) | -2.19 | -1.92 | -2.83 | -14.07 |
| Weighted average common shares outstanding, basic (in shares) | 14,000,451 | 10,829,760 | 5,546,257 | 1,034,130 |
| Weighted average common shares outstanding, diluted (in shares) | 14,000,451 | 10,829,760 | 10,784,037 | 7,653,302 |
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)